ArticleInvestigative ophthalmology & visual science2026
Route-Dependent Therapeutic Effects and Tissue Retention of Mesenchymal Stem Cell-Derived Exosomes in a Murine Model of Stevens-Johnson Syndrome.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Purpose: To test the therapeutic potential of mesenchymal stem cell-derived exosomes (MSC-exos) in ocular surface inflammation and to characterize immune responses in an IKAROS family zinc finger (IKZF) murine model of Stevens-Johnson syndrome (SJS) with allergic eye disease (AED). Methods: Transgenic mice expressing IKZF1 were used as the SJS model. To induce ocular surface inflammation, the mice were immunized with intraperitoneal ovalbumin in aluminum hydroxide (alum) and pertussis toxin and challenged with topical ovalbumin. Conjunctival tissues and draining lymph nodes (LNs) were analyzed by flow cytometry to characterize immune responses. MSC-exos were prepared from immortalized human embryonic stem cell-derived MSCs. Clinical disease was evaluated daily. The pharmacokinetics of Alexa Fluor 488-labeled MSC-exos were tracked using in vivo multiphoton confocal microscopy. Results: IKZF mice demonstrated increased conjunctival immune cell infiltration compared with wild-type controls, which was further amplified following allergic challenge. IKZF+AED mice exhibited expansion of innate and adaptive populations in the conjunctiva. Draining LNs showed increased frequencies of cytokine-producing CD4⁺ T cells. MSC-exo treatment significantly reduced clinical disease severity, with subconjunctival administration producing the greatest improvement, comparable to corticosteroid therapy. Pharmacokinetic imaging demonstrated rapid clearance of topically administered exosomes, whereas subconjunctival delivery resulted in retention within ocular tissues for up to 72 hours and localization within the conjunctival stroma. Conclusions: The IKZF+AED model demonstrates local conjunctival inflammation and systemic T-cell activation consistent with SJS-associated ocular disease. MSC-exos significantly improved clinical inflammation, and their therapeutic efficacy was strongly influenced by delivery route. Prolonged tissue retention following subconjunctival administration suggests that pharmacokinetic exposure within conjunctival tissues may be a key determinant of therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.